Transfusion in Critical Care — Part 4: Transfusion Reactions, Safety & Patient Blood Management
Recognition and management of all transfusion reactions (hemolytic, FNHTR, allergic, TRALI, TACO), TRALI vs TACO differential table, reporting requirements, patient blood management (PBM), special populations including Jehovah's Witness patients, and quality metrics.
1. Overview of Transfusion Reactions
Transfusion reactions encompass a spectrum of adverse events that may occur during or following blood product administration. Prompt recognition and appropriate management are essential to minimize morbidity and mortality. All transfusion reactions — regardless of severity — must be reported to the blood bank/transfusion service for investigation and regulatory documentation.1
1.1 Initial Response to Any Suspected Transfusion Reaction
When a transfusion reaction is suspected, the following steps should be taken immediately:
- STOP the transfusion — clamp the tubing; do not disconnect the blood product from the IV line
- Maintain IV access — keep the line open with normal saline through a separate access if possible
- Assess the patient — vital signs, oxygen saturation, respiratory status, urticaria/rash, urine output and color
- Notify the blood bank — report the reaction immediately
- Send the required specimens to the blood bank:
- The implicated blood product bag (with attached tubing)
- Post-transfusion blood sample (lavender-top EDTA tube) for direct antiglobulin test (DAT), visual plasma inspection for hemolysis, repeat type and screen
- Post-transfusion urine sample (inspect for hemoglobinuria)
- Send additional labs as clinically indicated: CBC, haptoglobin, LDH, indirect bilirubin, free hemoglobin, DIC panel (fibrinogen, D-dimer, PT/INR)
- Document the reaction in the medical record: time of onset, volume transfused, symptoms, vital sign changes, and management provided
2. Acute Transfusion Reactions — Classification and Management
2.1 Acute Hemolytic Transfusion Reaction (AHTR)
| Parameter | Details |
|---|---|
| Cause | ABO incompatibility (most severe — usually due to clerical/identification error); less commonly other alloantibodies |
| Mechanism | Recipient preformed antibodies (anti-A, anti-B) destroy transfused donor RBCs → complement activation → intravascular hemolysis → DIC, renal failure, shock |
| Incidence | 1:38,000 to 1:70,000 transfusions; fatal AHTR approximately 1:1,000,000 |
| Onset | Within minutes to hours of transfusion initiation; may occur after as little as 10–15 mL of incompatible blood |
| Symptoms/Signs | Fever, rigors, flank/back pain, chest pain, dyspnea, hypotension, tachycardia, hemoglobinuria (dark/cola-colored urine), anxiety, sensation of impending doom, diffuse oozing (DIC) |
| Laboratory findings | Positive DAT; elevated LDH; elevated indirect bilirubin; decreased haptoglobin (undetectable); free plasma hemoglobin elevated; hemoglobinuria; schistocytes (if DIC); elevated PT/INR, decreased fibrinogen (DIC) |
AHTR Emergency Management
| Step | Action |
|---|---|
| 1 | STOP transfusion immediately |
| 2 | Aggressive IV fluid resuscitation with normal saline to maintain renal perfusion and urine output > 1 mL/kg/h |
| 3 | Vasopressor support if hypotensive (norepinephrine or epinephrine as indicated) |
| 4 | Consider furosemide 40–80 mg IV if urine output inadequate despite adequate volume status (to maintain renal blood flow and prevent renal tubular obstruction by hemoglobin casts) |
| 5 | Monitor for and treat DIC — transfuse platelets, FFP, cryoprecipitate as needed for bleeding |
| 6 | Avoid additional incompatible transfusions — verify the correct blood product was given to the correct patient; recheck all identification bands, blood bank paperwork |
| 7 | Monitor in ICU setting; serial labs every 4–6 hours (hemoglobin, LDH, haptoglobin, bilirubin, renal function, coagulation panel) |
| 8 | Renal replacement therapy may be required for acute kidney injury due to hemoglobinuric nephropathy |
2.2 Febrile Non-Hemolytic Transfusion Reaction (FNHTR)
| Parameter | Details |
|---|---|
| Definition | Temperature rise ≥ 1°C (1.8°F) during or within 4 hours of transfusion, with no other identifiable cause |
| Cause | Cytokines accumulated in stored blood products (IL-1, IL-6, TNF-α); recipient antibodies against donor leukocyte antigens |
| Incidence | 0.1–1% (with pre-storage leukoreduction); historically 1–3% without leukoreduction |
| Symptoms | Fever, chills, rigors; may be accompanied by mild malaise; hemodynamically stable |
| Management | Stop transfusion; rule out hemolytic reaction and bacterial contamination (send transfusion reaction workup); administer acetaminophen 650–1,000 mg PO/IV and/or meperidine 25–50 mg IV for rigors; may cautiously restart transfusion once hemolytic reaction excluded (clinician judgment) |
| Prevention | Pre-storage leukoreduction (now universal in most countries); pre-medication with acetaminophen for patients with recurrent FNHTR (weak evidence for efficacy) |
2.3 Allergic Transfusion Reactions
Mild Allergic Reaction (Urticaria)
| Parameter | Details |
|---|---|
| Cause | Recipient IgE antibodies against donor plasma proteins |
| Incidence | 1–3% of transfusions |
| Symptoms | Urticaria (hives), pruritus; localized erythema; NO respiratory compromise, NO hypotension |
| Management | Pause transfusion (do not need to stop permanently for isolated urticaria); administer diphenhydramine 25–50 mg IV; if symptoms resolve within 30 minutes, may cautiously resume transfusion at a slower rate |
| Prevention | Pre-medication with diphenhydramine 25–50 mg IV/PO for patients with recurrent mild allergic reactions |
Severe Allergic / Anaphylactic Reaction
| Parameter | Details |
|---|---|
| Cause | Severe IgE-mediated reaction to donor plasma proteins; classically associated with IgA-deficient recipients who have anti-IgA antibodies (incidence of IgA deficiency: ~1:500; anti-IgA antibodies: rare) |
| Incidence | 1:20,000 to 1:50,000 transfusions |
| Symptoms | Urticaria, angioedema, bronchospasm, stridor, hypotension, tachycardia, abdominal cramping, nausea/vomiting; may progress to cardiovascular collapse; occurs within minutes of transfusion start |
| Management | STOP transfusion immediately; Epinephrine 0.3–0.5 mg IM (1:1,000) into lateral thigh — repeat every 5–15 min as needed; if refractory hypotension: epinephrine infusion 0.1–0.5 μg/kg/min IV; IV fluid bolus NS 500–1,000 mL; Albuterol nebulization for bronchospasm; Diphenhydramine 50 mg IV; Methylprednisolone 125 mg IV (for biphasic prevention); Airway management including intubation if compromised |
| Workup | IgA level and anti-IgA antibodies; tryptase level (if mast cell activation suspected) |
| Future transfusions | For confirmed IgA deficiency with anti-IgA: use washed blood products (RBCs, platelets) or products from IgA-deficient donors; for recurrent severe allergic reactions without IgA deficiency: use washed products |
2.4 Transfusion-Related Acute Lung Injury (TRALI)
TRALI is a potentially fatal complication characterized by acute hypoxemic respiratory failure within 6 hours of transfusion.2 3
| Parameter | Details |
|---|---|
| Definition (revised 2019) | New onset of: (1) Acute hypoxemia (PaO₂/FiO₂ ≤ 300 mmHg or SpO₂ < 90% on room air); (2) Bilateral pulmonary infiltrates on chest imaging; (3) No evidence of left atrial hypertension (no circulatory overload); (4) Onset within 6 hours of transfusion; (5) No pre-existing ALI/ARDS before transfusion; (6) No temporal relationship to an alternative risk factor for ALI |
| “Possible TRALI” | Meets TRALI criteria but a clear alternative risk factor for ALI is present (e.g., sepsis, pneumonia, aspiration) — termed “possible TRALI” as the transfusion contribution cannot be fully attributed |
| Mechanism | Two-hit model: First hit = patient factors (critical illness, sepsis, surgery) that prime neutrophils; Second hit = donor factors (anti-HLA Class I/II antibodies, anti-HNA antibodies, or bioactive lipids in stored blood) that activate primed neutrophils → neutrophil-mediated endothelial damage in pulmonary vasculature → noncardiogenic pulmonary edema |
| Incidence | 1:5,000 to 1:12,000 (decreasing with mitigation strategies); most commonly associated with plasma-containing products (FFP > platelets > RBCs) |
| Risk factors — Recipient | Critical illness, sepsis, mechanical ventilation, surgery, massive transfusion, chronic alcohol use, positive fluid balance |
| Risk factors — Donor | Female donors (especially multiparous — higher prevalence of HLA antibodies); this is the basis for male-predominant plasma policies |
| Mortality | 5–10% (lower than ARDS from other causes) |
| Onset | Typically within 1–2 hours of transfusion (by definition, within 6 hours) |
TRALI Management
| Step | Action |
|---|---|
| 1 | STOP transfusion immediately |
| 2 | Supportive care — this is the mainstay of treatment; no specific pharmacotherapy exists |
| 3 | Supplemental oxygen — escalate as needed (nasal cannula → high-flow nasal cannula → non-invasive ventilation → intubation and mechanical ventilation) |
| 4 | Mechanical ventilation if needed — use lung-protective ventilation strategy (tidal volume 6 mL/kg IBW, plateau pressure < 30 cmH₂O, PEEP titration per ARDSNet protocol) |
| 5 | Do NOT administer diuretics — TRALI is non-cardiogenic pulmonary edema; diuretics will worsen hypovolemia without addressing the underlying pathology |
| 6 | IV fluid resuscitation if hypotensive — patients with TRALI may be hypovolemic due to capillary leak |
| 7 | Vasopressors if needed for refractory hypotension |
| 8 | Notify the blood bank — all involved donors must be evaluated for HLA and HNA antibodies; implicated donors may be permanently deferred |
| 9 | Most patients improve within 48–72 hours with supportive care; chest imaging typically clears within 96 hours |
TRALI Mitigation Strategies
| Strategy | Details |
|---|---|
| Male-predominant plasma | Use plasma from male donors or from female donors who have never been pregnant or who test negative for HLA antibodies — reduces TRALI incidence by 50–80% |
| Platelet pathogen reduction | Pathogen reduction technology (e.g., amotosalen/UVA) may reduce TRALI risk by inactivating donor WBCs |
| Restrictive transfusion practices | Fewer transfusions = fewer opportunities for TRALI |
2.5 Transfusion-Associated Circulatory Overload (TACO)
TACO is the most common cause of transfusion-related mortality reported to regulatory agencies and is likely significantly underrecognized.4
| Parameter | Details |
|---|---|
| Definition | New or worsening respiratory distress within 6 hours (recently expanded to 12 hours) of transfusion, characterized by at least 3 of 5: (1) acute respiratory distress; (2) elevated BNP (> 1.5× pre-transfusion level); (3) elevated CVP or JVP; (4) evidence of positive fluid balance; (5) left heart failure on echocardiography |
| Mechanism | Circulatory volume overload → hydrostatic pulmonary edema |
| Incidence | 1:100 to 1:700 transfusions (most common serious transfusion reaction) |
| Risk factors | Age > 70; congestive heart failure; renal insufficiency; positive fluid balance; rapid transfusion rate; large transfusion volume; small body habitus |
| Onset | During or within 6–12 hours of transfusion |
| Symptoms | Dyspnea, orthopnea, cough, chest tightness, hypertension, tachycardia, jugular venous distension, pulmonary crackles/rales, peripheral edema, hypoxemia |
TACO Management
| Step | Action |
|---|---|
| 1 | STOP or slow the transfusion |
| 2 | Position patient upright (semi-Fowler’s or Fowler’s position) |
| 3 | Supplemental oxygen to maintain SpO₂ > 92% |
| 4 | Diuretics — Furosemide 20–40 mg IV (higher dose if chronic diuretic use or renal impairment); repeat as needed based on clinical response and urine output |
| 5 | Non-invasive positive-pressure ventilation (BiPAP/CPAP) if diuretics and oxygen insufficient |
| 6 | Intubation if refractory hypoxemia or respiratory failure |
| 7 | For future transfusions: slow infusion rate (1 unit over 3–4 hours); consider pre-transfusion diuretics (furosemide 20 mg IV between units); limit to single-unit transfusion with reassessment; avoid concurrent IV fluids if possible |
2.6 TRALI vs TACO — Differential Diagnosis Table
This is one of the most important clinical distinctions in transfusion medicine, as the management of TRALI and TACO are fundamentally different.2 4
| Feature | TRALI | TACO |
|---|---|---|
| Mechanism | Non-cardiogenic pulmonary edema (increased capillary permeability — immune-mediated neutrophil activation) | Cardiogenic/hydrostatic pulmonary edema (volume overload) |
| Onset | Within 6 hours of transfusion (typically 1–2 hours) | During or within 6–12 hours of transfusion |
| Blood pressure | Hypotension (common) | Hypertension (common) |
| Temperature | Fever common | Usually afebrile |
| Jugular venous pressure | Normal or low | Elevated |
| BNP / NT-proBNP | Normal or mildly elevated | Markedly elevated (> 1.5× pre-transfusion baseline is suggestive) |
| Pulmonary edema fluid | Exudative (edema fluid-to-serum protein ratio > 0.65) | Transudative (edema fluid-to-serum protein ratio < 0.65) |
| Chest X-ray | Bilateral infiltrates (may be asymmetric); no cardiomegaly; no vascular congestion/cephalization | Bilateral infiltrates with cardiomegaly, vascular congestion, cephalization, pleural effusions |
| Echocardiography | Normal LV function; no elevated filling pressures | Elevated filling pressures; may show LV dysfunction |
| Fluid balance | May be negative or even | Typically positive |
| Response to diuretics | No improvement (and may worsen hypotension) | Rapid improvement |
| Treatment | Supportive care; lung-protective ventilation if needed; IV fluids for hypotension; NO diuretics | Diuretics; upright positioning; slow or stop transfusion; oxygen; NIV if needed |
| Prognosis | Most improve within 48–72 hours; mortality 5–10% | Mortality 5–15%; higher in elderly with comorbidities |
| Recurrence with future transfusion | Low (if implicated donor is deferred) | High (especially if risk factors persist) |
| Reporting | Mandatory reporting to blood bank; donor investigation required | Report to blood bank; no donor investigation needed |
2.7 Bacterial Contamination
| Parameter | Details |
|---|---|
| Incidence | RBC contamination: 1:250,000; platelet contamination: 1:75,000 (higher because platelets stored at room temperature) |
| Common organisms | RBCs: Yersinia enterocolitica (classic cold-growing organism), Serratia, Pseudomonas; Platelets: Staphylococcus spp., Streptococcus spp., gram-negative rods (Klebsiella, E. coli) |
| Symptoms | High fever (≥ 2°C rise), rigors, hypotension, tachycardia; may rapidly progress to septic shock; onset typically within 30 minutes to 4 hours of transfusion start |
| Management | STOP transfusion; blood cultures from patient (peripheral and through the transfusion line); Gram stain and culture of the blood product bag; broad-spectrum antibiotics immediately (piperacillin-tazobactam or meropenem + vancomycin); hemodynamic support per sepsis protocols |
| Mitigation | Bacterial testing of platelet products (now mandatory in many jurisdictions); pathogen reduction technology; visual inspection of products before transfusion; maintain cold chain for RBCs |
2.8 Delayed Hemolytic Transfusion Reaction (DHTR)
| Parameter | Details |
|---|---|
| Onset | 3–28 days after transfusion (typically 5–10 days) |
| Mechanism | Anamnestic antibody response — patient was previously alloimmunized (often undetected because antibody titer had fallen below detection); re-exposure to antigen on transfused RBCs triggers anamnestic antibody production → extravascular hemolysis |
| Common antibodies | Anti-Jkᵃ (Kidd — classically associated with delayed reactions because Kidd antibodies are notorious for “disappearing” and re-emerging), anti-E, anti-K, anti-Fyᵃ, anti-c |
| Symptoms | Often asymptomatic; may present with unexplained hemoglobin drop, jaundice, dark urine, low-grade fever; rarely severe (but can be severe in sickle cell disease — hyperhemolysis syndrome) |
| Diagnosis | Positive DAT (new antibody coating transfused RBCs); newly identified alloantibody on antibody screen; elevated LDH, indirect bilirubin; decreased haptoglobin |
| Management | Usually self-limited; transfuse with antigen-negative, crossmatch-compatible blood if additional transfusion needed; notify blood bank for antibody identification and permanent record update |
| Prevention | Antibody identification cards; blood bank permanent records; extended phenotyping/genotyping for chronically transfused patients (especially sickle cell disease) |
2.9 Other Transfusion Reactions
| Reaction | Description | Management |
|---|---|---|
| Transfusion-associated graft-versus-host disease (TA-GVHD) | Engraftment of donor T-lymphocytes that attack recipient tissues (skin, liver, GI tract, bone marrow); nearly 100% fatal; occurs 4–30 days post-transfusion; most common in immunocompromised patients or when donor is homozygous for an HLA haplotype shared with the recipient | Prevention with irradiation of cellular products (RBCs and platelets) for at-risk patients; no effective treatment once established |
| Post-transfusion purpura (PTP) | Severe thrombocytopenia 5–10 days after transfusion; caused by platelet-specific alloantibodies (anti-HPA-1a most common) that destroy both donor and recipient platelets; rare | IVIG 1 g/kg/day × 2 days; platelet transfusion usually ineffective |
| Iron overload | Chronic transfusion-dependent patients (thalassemia, MDS, sickle cell disease); each unit of RBCs contains ~200–250 mg iron; body has no physiologic excretion mechanism | Monitor ferritin; iron chelation therapy (deferasirox, deferoxamine, deferiprone) when ferritin > 1,000 ng/mL or after ~20 units of RBCs |
| Hypotensive transfusion reaction | Isolated hypotension (SBP drop ≥ 30 mmHg) without other features of hemolytic, allergic, or septic reaction; associated with bedside leukoreduction filters and ACE inhibitor use | Stop transfusion; IV fluids; consider discontinuing ACE inhibitors prior to future transfusions |
| Citrate toxicity | Metabolic alkalosis (from citrate → bicarbonate conversion) and hypocalcemia during massive transfusion | Calcium replacement (see Part 3); monitor ionized calcium |
| Hyperkalemia | Potassium leaches from stored RBCs (older units have higher K⁺ levels — up to 50 mEq/L in supernatant by day 42); risk in massive transfusion, renal failure, neonates | Monitor potassium; use fresher units for neonates and rapid/massive transfusion; standard hyperkalemia treatment if needed (calcium, insulin/dextrose, sodium bicarbonate) |
2.10 Reporting Requirements
| Requirement | Details |
|---|---|
| Blood bank notification | ALL suspected transfusion reactions must be reported to the blood bank/transfusion service immediately — this is mandatory |
| Transfusion reaction investigation | The blood bank performs: clerical check (verify correct patient received correct product), DAT, visual inspection of post-transfusion plasma for hemolysis, repeat ABO/Rh typing |
| Institutional reporting | Report to institutional transfusion committee and quality/safety department |
| Regulatory reporting | Fatal transfusion reactions must be reported to the national regulatory agency (e.g., FDA in the US; SHOT in the UK) |
| Documentation | Complete documentation in the medical record: product transfused (unit number, component type), time reaction occurred, signs and symptoms, vital signs, treatment provided, outcome |
3. Special Populations
3.1 Cardiac Surgery
| Aspect | Recommendation |
|---|---|
| RBC transfusion threshold | Hb ≤ 7.5 g/dL (TRICS-III)5; some cardiac surgeons use Hb ≤ 9 g/dL on CPB due to hemodilution |
| Cell salvage | Intraoperative cell salvage (autotransfusion) is recommended for all cardiac surgery; reduces allogeneic transfusion by 30–40% |
| Antifibrinolytics | TXA is the standard of care for cardiac surgery: Loading dose 10–30 mg/kg IV before incision; Maintenance 1–16 mg/kg/h during surgery; may add dose to CPB circuit prime. Evidence: ATACAS trial demonstrated TXA reduced blood loss and transfusion without increasing thrombosis6; higher doses (> 100 mg/kg cumulative) associated with increased seizure risk |
| Aminocaproic acid | Alternative to TXA: Loading dose 5 g IV, then 1 g/h maintenance; lower cost than TXA; may have slightly lower efficacy |
| Platelet transfusion | CPB causes platelet dysfunction (activation, degranulation, partial consumption); platelet count alone may not reflect functional impairment; consider TEG/ROTEM-guided platelet transfusion; desmopressin (DDAVP) 0.3 μg/kg IV may improve platelet function post-CPB |
| Fibrinogen replacement | Fibrinogen is often the first factor to reach critical levels post-CPB; ROTEM FIBTEM-guided replacement (target FIBTEM A5 ≥ 8–12 mm) with cryoprecipitate or fibrinogen concentrate7 |
| Point-of-care testing | TEG/ROTEM-guided transfusion algorithms reduce transfusion requirements by 20–30% compared to empiric transfusion in cardiac surgery |
3.2 Traumatic Brain Injury (TBI)
| Aspect | Recommendation |
|---|---|
| RBC threshold | Hb ≤ 7 g/dL (general recommendation); some neurocritical care guidelines recommend Hb ≤ 10 g/dL to optimize cerebral oxygen delivery; evidence is limited (Robertson et al. trial was underpowered)8 |
| Platelet threshold | Maintain platelets > 100,000/μL in patients with intracranial hemorrhage |
| Anticoagulation reversal | Rapid reversal of all anticoagulants (warfarin: 4-factor PCC + vitamin K; DOACs: specific reversal agents; heparin: protamine); correct coagulopathy (INR ≤ 1.4) urgently |
| Permissive hypotension | Contraindicated in TBI — avoid SBP < 100 mmHg; target CPP ≥ 60 mmHg |
| TXA | CRASH-3 trial showed TXA may reduce head-injury-related death in patients with mild-to-moderate TBI (GCS 9–15) when given within 3 hours; no benefit in severe TBI (GCS 3–8); dose: 1 g IV bolus + 1 g over 8 hours9 |
3.3 Sepsis
| Aspect | Recommendation |
|---|---|
| RBC threshold | Hb ≤ 7 g/dL (TRISS trial — strong recommendation)10 |
| Platelet threshold | < 10,000/μL prophylactic; < 50,000/μL if bleeding or invasive procedures |
| DIC management | Per DIC transfusion protocol (see Part 2, Section 4) |
| No benefit of supranormal DO₂ | The Rivers EGDT trial used ScvO₂-targeted transfusion (Hb > 10 g/dL if ScvO₂ < 70%); subsequent trials (ProCESS, ARISE, ProMISe) did not confirm benefit of this strategy; current guidelines recommend restrictive Hb ≤ 7 g/dL with clinical assessment |
3.4 ECMO
| Aspect | Recommendation |
|---|---|
| RBC threshold | Hb ≤ 7 g/dL (extrapolated from general ICU evidence; the Extracorporeal Life Support Organization guidelines suggest individualized targets)11 |
| Anticoagulation | ECMO circuits require systemic anticoagulation (UFH targeting aPTT 1.5–2.5× or anti-Xa 0.3–0.7 IU/mL); increases bleeding risk |
| Acquired von Willebrand syndrome | High shear forces in ECMO circuit cause degradation of large vWF multimers → acquired vWD; may contribute to mucosal bleeding; diagnosis: vWF activity/antigen ratio < 0.7; management: reduce ECMO flow if possible, DDAVP, vWF concentrate |
| Hemolysis | ECMO circuits cause mechanical hemolysis; monitor free hemoglobin, LDH, haptoglobin; adjust circuit if free Hb > 50 mg/dL |
| Platelet consumption | ECMO circuits consume platelets; maintain platelets > 50,000/μL (> 80,000–100,000/μL if actively bleeding) |
3.5 Jehovah’s Witness / Transfusion Refusal
| Aspect | Recommendation |
|---|---|
| Legal and ethical framework | Competent adult patients have the legal right to refuse blood transfusion, even in life-threatening situations; this is well-established in medical ethics and case law; document the refusal clearly; obtain signed refusal of blood products form |
| Advance documentation | Discuss and document the patient’s specific wishes regarding each blood product: some patients accept certain fractions (albumin, immunoglobulins, clotting factors, EPO) but not whole blood, RBCs, plasma, or platelets; some accept cell salvage if circuit remains in continuous connection with the patient |
| Accepted alternatives (varies by individual) | Erythropoietin (EPO) — preoperative optimization; IV iron (ferric carboxymaltose, iron sucrose); acute normovolemic hemodilution (ANH) — if blood remains in continuous circuit; cell salvage — if continuous circuit maintained; fibrin sealants; antifibrinolytics (TXA); desmopressin (DDAVP); recombinant Factor VIIa (off-label); albumin (accepted by many); immunoglobulins (accepted by many) |
| Preoperative optimization | Maximize hemoglobin preoperatively: oral/IV iron, EPO, folate, B12; correct coagulopathy without blood products; minimize blood loss (meticulous surgical technique, antifibrinolytics, topical hemostatic agents); acute normovolemic hemodilution |
| Intraoperative strategies | Cell salvage (with continuous circuit); controlled hypotension; antifibrinolytics; meticulous hemostasis; minimize phlebotomy (pediatric tubes, point-of-care testing) |
| Emergency situations | If a patient is unconscious and their transfusion preferences are unknown, standard of care applies (transfuse if indicated); if a valid advance directive refusing blood is documented, this must be respected even in emergencies; for minor children of Jehovah’s Witness parents, courts can and do order blood transfusion over parental objection when the child’s life is at risk |
| Pediatric considerations | Minors cannot legally refuse life-saving treatment — if parents refuse blood transfusion for a child and transfusion is medically necessary, the clinical team should involve hospital legal counsel and may petition for emergency court order; most jurisdictions will override parental refusal for life-threatening situations |
4. Patient Blood Management (PBM)
Patient blood management is a systematic, evidence-based approach to optimizing the care of patients who might need transfusion. PBM rests on three pillars designed to minimize unnecessary exposure to allogeneic blood products while optimizing patient outcomes.12
4.1 The Three Pillars of PBM
| Pillar | Strategy | Implementation |
|---|---|---|
| Pillar 1: Optimize Erythropoiesis | Detect and treat anemia before surgery or during critical illness | Preoperative anemia screening (ideally 4–6 weeks before elective surgery); IV iron for iron deficiency (ferric carboxymaltose 1,000 mg IV or iron sucrose 200–300 mg IV); erythropoietin (EPO) 300–600 IU/kg SC weekly × 3–4 doses for select preoperative patients; folate and B12 replacement if deficient; avoid unnecessary phlebotomy in the ICU |
| Pillar 2: Minimize Blood Loss | Reduce surgical and procedural blood loss; minimize iatrogenic blood loss | Antifibrinolytics (TXA, aminocaproic acid); cell salvage; meticulous surgical technique and hemostasis; topical hemostatic agents; point-of-care testing (reduce lab blood volumes); minimize phlebotomy (use pediatric tubes in ICU — reduces iatrogenic blood loss by 30–50%); avoid unnecessary arterial line blood draws |
| Pillar 3: Optimize Tolerance of Anemia | Manage anemia without transfusion when appropriate; apply restrictive transfusion thresholds | Restrictive transfusion thresholds (Hb ≤ 7 g/dL for most ICU patients); single-unit transfusion policy; optimize oxygen delivery (ventilation, oxygenation, cardiac output); reduce oxygen consumption (treat fever, pain, agitation); supplemental oxygen |
4.2 Preoperative Anemia Optimization
| Component | Details |
|---|---|
| Screening | All patients scheduled for elective surgery with expected blood loss > 500 mL should have CBC screened ≥ 4 weeks preoperatively |
| Iron deficiency anemia | IV iron preferred over oral (faster repletion, better GI tolerance); Ferric carboxymaltose 1,000 mg IV single dose or iron sucrose 200–300 mg IV × 3–5 doses; expect Hb rise of 1–2 g/dL over 2–4 weeks |
| Functional iron deficiency (transferrin saturation < 20%, ferritin 100–300 ng/mL) | IV iron supplementation; may benefit from EPO in combination |
| EPO | Short-course EPO (300–600 IU/kg SC weekly × 3–4 weeks) may be considered for patients with anemia of chronic disease or when IV iron alone is insufficient; risk of thrombosis must be considered |
| B12/Folate deficiency | Replace prior to surgery; cyanocobalamin 1,000 μg IM/SC daily × 7 days then weekly; folate 1 mg PO daily |
| Goal | Hb ≥ 13 g/dL (males) or ≥ 12 g/dL (females) preoperatively; or optimize as close to normal as possible |
4.3 Cell Salvage (Intraoperative Autotransfusion)
| Parameter | Details |
|---|---|
| Mechanism | Shed blood is collected from the surgical field, washed (centrifuged), and returned to the patient as washed autologous RBCs |
| Indications | Any surgery with expected blood loss > 500 mL — cardiac surgery, major orthopedic (spine, joint replacement), vascular surgery, liver transplantation, obstetric hemorrhage (with leukocyte depletion filter) |
| Advantages | Reduces allogeneic transfusion; immediate availability; no compatibility testing required; accepted by some Jehovah’s Witness patients (if circuit remains continuous) |
| Contraindications (relative) | Malignancy (theoretical risk of tumor cell dissemination — use leukocyte depletion filter if used); contaminated surgical field (bowel contents — use in combination with broad-spectrum antibiotics); sickle cell disease (hemolysis risk) |
| Expected product | Hematocrit 50–80%; free of plasma proteins, platelets, and coagulation factors (washed out); free of most WBCs |
4.4 Point-of-Care Testing-Guided Transfusion
POC testing (TEG/ROTEM) enables goal-directed, algorithm-driven transfusion that reduces unnecessary blood product use while improving hemostatic outcomes (see Part 3, Section 3 for detailed TEG/ROTEM interpretation).
Evidence from randomized trials in cardiac surgery demonstrates that TEG/ROTEM-guided transfusion algorithms reduce:13
- Total blood products transfused by 20–30%
- Platelet transfusion by 30–40%
- Plasma transfusion by 20–30%
- Surgical re-exploration rates
- Hospital length of stay
4.5 Minimizing Iatrogenic Blood Loss in the ICU
| Strategy | Details | Expected Impact |
|---|---|---|
| Pediatric blood collection tubes | Use pediatric (small-volume) tubes for all ICU lab draws | Reduces phlebotomy blood loss by 30–50% (from ~40–70 mL/day to ~15–30 mL/day) |
| Point-of-care testing | Use POC devices (ABG, lactate, electrolytes, glucose, hemoglobin) that require < 0.5 mL per test | Reduces lab blood volumes significantly |
| Bundle lab orders | Eliminate redundant or unnecessary lab orders; avoid routine daily labs when not clinically indicated | Reduces phlebotomy frequency |
| Closed arterial line sampling systems | Use closed sampling systems that return discarded blood to the patient | Eliminates ~2–5 mL waste per arterial draw |
| Limit routine surveillance labs | Question the need for daily CBC, CMP, and coagulation studies in stable patients | Each lab draw removes 3–10 mL of blood; daily draws in the ICU can cause hospital-acquired anemia |
5. Quality Metrics and Performance Improvement
5.1 Key Transfusion Quality Metrics
| Metric | Description | Target |
|---|---|---|
| Restrictive threshold compliance | Percentage of RBC transfusions given at Hb ≤ 7 g/dL (or population-appropriate threshold) | > 80% of non-bleeding transfusions |
| Single-unit transfusion rate | Percentage of RBC transfusion orders that are for a single unit | > 70% of stable (non-MTP) transfusions |
| Appropriateness of platelet transfusion | Percentage of platelet transfusions meeting evidence-based indications | > 85% |
| Appropriateness of plasma transfusion | Percentage of plasma transfusions meeting evidence-based indications (active bleeding with INR > 1.5, MTP, DIC with bleeding) | > 80% |
| Transfusion reaction reporting rate | Percentage of transfusion reactions reported to the blood bank | 100% (all reactions must be reported) |
| Blood product wastage rate | Percentage of blood products issued but not transfused (expired, returned, discarded) | < 5% for RBCs; < 10% for platelets |
| MTP activation appropriateness | Percentage of MTP activations that resulted in ≥ 10 units RBC or met massive transfusion criteria | > 50% (over-activation is acceptable to ensure availability; under-activation is harmful) |
| Pre-transfusion Hb documentation | Percentage of transfusion orders with a documented pre-transfusion hemoglobin | 100% |
| Type and screen turnaround time | Time from sample receipt to result availability | < 60 minutes |
| Emergency release turnaround | Time from request to uncrossmatched blood product issuance | < 10 minutes |
5.2 Transfusion Committee
Every hospital with a transfusion service should maintain an active Transfusion Committee (or equivalent quality oversight body) that:
- Reviews transfusion utilization data monthly or quarterly
- Conducts retrospective audits of transfusion appropriateness
- Investigates transfusion reactions and near-miss events
- Develops and updates institutional transfusion guidelines and protocols
- Monitors compliance with restrictive transfusion practices
- Oversees the massive transfusion protocol
- Reports to hospital quality and safety leadership
- Includes representation from: transfusion medicine/pathology, hematology, surgery, anesthesiology, critical care, nursing, and blood bank
5.3 Electronic Clinical Decision Support
Computerized provider order entry (CPOE) systems can incorporate clinical decision support tools for transfusion ordering:14
- Best-practice alerts when RBC transfusion ordered at Hb > 7 g/dL (or > 8 g/dL for ACS) — requiring justification documentation
- Default single-unit orders — require re-ordering for each additional unit
- Appropriateness prompts for plasma transfusion when INR < 1.5
- Automatic platelet threshold verification — alert when platelet transfusion ordered above evidence-based threshold
- MTP order sets — standardized component orders to ensure balanced-ratio transfusion
References
Delaney M, Wendel S, Bercovitz RS, et al. “Transfusion Reactions: Prevention, Diagnosis, and Treatment.” Lancet. 2016;388(10061):2825-2836. DOI: 10.1016/S0140-6736(15)01313-6 ↩︎
Vlaar APJ, Toy P, Fung M, et al. “A Consensus Redefinition of Transfusion-Related Acute Lung Injury.” Transfusion. 2019;59(7):2465-2476. DOI: 10.1111/trf.15311 ↩︎ ↩︎
Toy P, Gajic O, Bacchetti P, et al. “Transfusion-Related Acute Lung Injury: Incidence and Risk Factors.” Blood. 2012;119(7):1757-1767. DOI: 10.1182/blood-2011-08-370932 ↩︎
Roubinian NH, Hendrickson JE, Engoren M, et al. “Transfusion-Associated Circulatory Overload.” Transfusion. 2022;62(12):2643-2655. DOI: 10.1111/trf.17150 ↩︎ ↩︎
Mazer CD, Whitlock RP, Fergusson DA, et al. “Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery.” N Engl J Med. 2017;377(22):2133-2144. DOI: 10.1056/NEJMoa1711818 ↩︎
Myles PS, Smith JA, Forbes A, et al. “Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.” N Engl J Med. 2017;376(2):136-148. DOI: 10.1056/NEJMoa1606424 ↩︎
Rahe-Meyer N, Solomon C, Hanke A, et al. “Effects of Fibrinogen Concentrate as First-Line Therapy during Major Aortic Replacement Surgery: A Randomized, Placebo-Controlled Trial.” Anesthesiology. 2013;118(1):40-50. DOI: 10.1097/ALN.0b013e3182715d4d ↩︎
Robertson CS, Hannay HJ, Yamal JM, et al. “Effect of Erythropoietin and Transfusion Threshold on Neurological Recovery after Traumatic Brain Injury: A Randomized Clinical Trial.” JAMA. 2014;312(1):36-47. DOI: 10.1001/jama.2014.6490 ↩︎
CRASH-3 trial collaborators. “Effects of Tranexamic Acid on Death, Disability, Vascular Occlusive Events and Other Morbidities in Patients with Acute Traumatic Brain Injury (CRASH-3): A Randomised, Placebo-Controlled Trial.” Lancet. 2019;394(10210):1713-1723. DOI: 10.1016/S0140-6736(19)32233-0 ↩︎
Holst LB, Haase N, Wetterslev J, et al. “Lower versus Higher Hemoglobin Threshold for Transfusion in Septic Shock.” N Engl J Med. 2014;371(15):1381-1391. DOI: 10.1056/NEJMoa1406617 ↩︎
Extracorporeal Life Support Organization. “ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support.” Version 1.4. 2017. Available at: https://www.elso.org/resources/guidelines.aspx ↩︎
Meybohm P, Herrmann E, Steinbicker AU, et al. “Patient Blood Management is Associated with a Substantial Reduction of Red Blood Cell Utilization and Safe for Patient’s Outcome: A Prospective, Multicenter Cohort Study with a Noninferiority Design.” Ann Surg. 2016;264(2):203-211. DOI: 10.1097/SLA.0000000000001747 ↩︎
Serraino GF, Murphy GJ. “Routine Use of Viscoelastic Blood Tests for Diagnosis and Treatment of Coagulopathic Bleeding in Cardiac Surgery: Updated Systematic Review and Meta-Analysis.” Br J Anaesth. 2017;118(6):823-833. DOI: 10.1093/bja/aex100 ↩︎
Hibbs SP, Nielsen ND, Brunskill S, et al. “The Impact of Electronic Decision Support on Transfusion Practice: A Systematic Review.” Transfus Med Rev. 2015;29(1):14-23. DOI: 10.1016/j.tmrv.2014.09.002 ↩︎